R Squared’s Definium Therapeutics DFTX Stock Holding History

R Squared’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-450	Closed	-$3.13K	–	1014
2024 Q4	$3.13K	Buy	+450	New	+$3.1K	﹤0.01%	1403

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's DFTX Position: Q1 2025 in Review

R Squared sold out of Definium Therapeutics (DFTX) in Q1 2025, closing a stake of 450 shares — an estimated $3.13K sold.

R Squared first reported a position in DFTX in Q4 2024 and held it in 1 quarter. The position peaked at $3.13K in Q4 2024. 190 funds tracked by Wall St. Rank hold DFTX as of Q1 2025.

R Squared reported no remaining Definium Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 450 Definium Therapeutics shares in Q1 2025, an estimated $3.13K.
R Squared first reported a position in Definium Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Definium Therapeutics position peaked at $3.13K in Q4 2024.
190 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.